Incretin Atlas › Trials › REDEFINE 1
REDEFINE 1
CagriSema · obesity
Design
- Molecule(s)
- CagriSema
- Population
- obesity
- Official title
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- active not recruiting · 2022-11 → 2024-10
- Participants
- 3417
- Duration
- 68 weeks
- Registry
- NCT05567796
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CagriSema 2.4/2.4 mg | obesity | 68 | 3417 | −22.7 % vs −2.3 % Δ −20.4 pp | −20.4 % vs −3.0 % Δ −17.4 pp | — | 5.9 vs 3.5 | 11.8 vs 24.1 | — | — | 9.8 vs 6.1 | −9.9 vs −3.2 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- CagriSema 2.4/2.4 mg: Any discontinuation = 100 − % still on drug at week 68.
Verbatim quotes from the source (6)
- CagriSema 2.4/2.4 mg · weight_eff · Results, Efficacy, Body-Weight Reduction; Fig 1B
On the basis of the trial-product estimand, the percent weight reduction was −22.7% with cagrilintide–semaglutide and −2.3% with placebo
- CagriSema 2.4/2.4 mg · weight_tp · Table 2; Results, Efficacy
the mean percent body-weight reduction at week 68 was −20.4% with cagrilintide–semaglutide and −3.0% with placebo
- CagriSema 2.4/2.4 mg · ae_dc · Table 3; Results, Safety
discontinued because of adverse events (5.9% vs. 3.6%, 2.6%, and 3.5%, respectively)
- CagriSema 2.4/2.4 mg · sae · Table 3; Results, Safety
Serious adverse events were reported in 9.8% of the participants receiving cagrilintide–semaglutide
- CagriSema 2.4/2.4 mg · sbp · Table 2; Results, Additional End Points
The mean reduction from baseline to week 68 in systolic blood pressure was −9.9 mm Hg with cagrilintide–semaglutide and −3.2 mm Hg with placebo
- CagriSema 2.4/2.4 mg · disc_any · Results, Participants
The percentage of participants still receiving the drug or placebo at week 68 was 88.2% in the cagrilintide–semaglutide group, 91.4% in the semaglutide group, 87.7% in the cagrilintide group, and 75.9% in the placebo gro
Primary sources
- Novo Nordisk A/S. Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity (REDEFINE 1). ClinicalTrials.gov identifier NCT05567796. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05567796
- Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647. PMID: 40544433.
How to cite this page
Medical Adviser's Group. Incretin Atlas: REDEFINE 1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.